Scalable biotech platform for sustainable peptide production
Numaferm's Numaswitch™ platform offers scalable, efficient peptide production using advanced fermentation technology, achieving high purities and yields. It supports various project scales, aligning with regulatory standards, providing a reliable and cost-effective peptide supply.
Overview
Numaferm introduces the Numaswitch™ platform, a cutting-edge solution for peptide production. This biotechnology platform integrates advanced fermentation technology with unique bifunctional Switchtag proteins and a proprietary protease system to deliver high-quality peptides. Designed for scalability and sustainability, it ensures a reliable supply chain for diverse peptide targets, meeting both Non-GMP and GMP regulatory standards. This platform is ideal for clients seeking cost-efficient and timely peptide production across various project scales.
Technical specifications
- Numaswitch™ technology: Proven success in over 100 projects, achieving yields of up to 5g/L of purified peptide.
- Purity and scalability: Capable of producing peptides with ≥99% purity, supporting 10g batch production for pre-clinical studies.
- Quality standards: Operates under ISO 9001:2015 certified quality management system.
- Flexible production: Adaptable for peptides of various lengths and physicochemical properties.
- Comprehensive support: Includes process development, transfer capabilities, and client training for seamless integration.
Technology readiness level
The Numaswitch™ platform is at Technology Readiness Level 9, indicating full commercial deployment and proven efficacy in large-scale peptide production.
About Numaferm
Numaferm is a German biotechnology company based in Düsseldorf that specializes in the recombinant production of peptides, proteins, and pepteins. Founded in 2017, the company utilizes proprietary technology platforms, including Numascreen for lead discovery and Numatech for scalable expression. These solutions enable the development and manufacturing of complex molecules, particularly those in the range of 30-500 amino acids, which are often difficult to produce using traditional chemical synthesis or standard recombinant methods. The company operates in accordance with ISO 9001:2015 standards and maintains a partner network of contract manufacturing organizations to facilitate scale-up and commercial production.
By providing efficient, sustainable, and cost-effective production processes, Numaferm supports partners in the pharmaceutical, biotech, cosmetic, and agricultural industries. The company offers end-to-end services, ranging from initial lead discovery and cell line development to the implementation of analytics and GMP-compliant material supply. Numaferm has demonstrated its capabilities through numerous successful projects and strategic collaborations, such as a licensing agreement with Zoetis for the development of veterinary therapeutics. Their platform technology aims to remove cost-related barriers to innovation, helping customers accelerate the development of safer and more effective products.
delivered to your inbox.